Premium
Association of High Mobility Group Box Chromosomal Protein 1 and Receptor for Advanced Glycation End Products Serum Concentrations With Extraglandular Involvement and Disease Activity in Sjögren's Syndrome
Author(s) -
Kanne AnnaMaria,
Jülich Maike,
Mahmutovic Amira,
Tröster Isabella,
Sehnert Bettina,
Urbonaviciute Vilma,
Voll Reinhard E.,
Kollert Florian
Publication year - 2018
Publication title -
arthritis care and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.032
H-Index - 163
eISSN - 2151-4658
pISSN - 2151-464X
DOI - 10.1002/acr.23420
Subject(s) - medicine , blot , rheumatism , glycation , gastroenterology , autoantibody , receptor , disease , immunology , endocrinology , antibody , biology , biochemistry , gene
Objective To assess serum levels of high mobility group box chromosomal protein 1 ( HMGB ‐1) and the soluble receptor for advanced glycation end products ( sRAGE ) in patients with Sjögren's syndrome ( SS ) and explore correlations with disease activity. Methods Thirty‐nine patients with SS and 21 healthy controls were included in this cross‐sectional study. Clinical and laboratory values were obtained from all patients. Disease activity was assessed using the European League Against Rheumatism SS Disease Activity Index ( ESSDAI ). Serum samples were collected and HMGB ‐1 and sRAGE levels were measured using enzyme‐linked immunosorbent assay ( ELISA ), and HMGB ‐1 concentrations were semiquantified by Western blotting. Results In ELISA , HMGB ‐1 serum levels did not differ between healthy controls and patients with SS ( P = 0.783). When measured by semiquantitative Western blotting, HMGB ‐1 levels were increased in patients with SS compared to healthy controls ( P = 0.012). HMGB ‐1 serum levels detected by Western blotting were higher in patients with extraglandular manifestations ( P = 0.003) and were correlated with ESSDAI disease activity (r = 0.544, P < 0.0001). Furthermore, sRAGE was elevated in the sera of patients with SS ( P = 0.003) compared to healthy controls and was also correlated with the ESSDAI (r = 0.545, P = 0.002). Conclusion Serum levels of total HMGB ‐1 and sRAGE were elevated in patients with SS compared to healthy controls and correlated with disease activity as measured by the ESSDAI . Patients with extraglandular involvement had high serum levels of HMGB ‐1.